TPMs have several additional features that enhance its tumor selectivity, promote its penetration into peritoneal tumors, reduce its host toxicity and provide rapid onset, as well as sustained ...

Since the clinical development of siRNA cancer therapeutics is limited by the poor interstitial transport and inefficient transfection in solid tumors, we explored the possibility of using tumor ...